Coronary Heart Disease Clinical Trials

Find Coronary Heart Disease Clinical Trials Near You

Evaluation of the Efficacy and Safety of XTR004 Injection in Detecting Blood Flow Restrictive Stenosis in Patients With Suspected or Known Stable Coronary Artery Disease: A Multicenter, Open-Label, Phase III Clinical Trial

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The primary objective of this study is to evaluate the effectiveness of visual reading in XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards in patients with suspected or known coronary artery disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Participants aged 18 to 80 years, male or female.

• Suspected or confirmed patients with stable coronary heart disease. Those suspected of having stable coronary heart disease must meet at least one of the following risk factors: hypertension, hyperlipidemia, diabetes, obesity (BMI ≥28), a history of alcohol abuse, a smoking history, a family history of coronary heart disease, postmenopausal status, or age 60 years or older.

• Participants can communicate well with investigators, understand and comply with clinical trial requirements, voluntarily participate in the study, and sign an informed consent form.

Locations
Other Locations
China
Beijing Anzhen Hospital, Capital Medical University
RECRUITING
Beijing
Beijing Tongren Hospital
RECRUITING
Beijing
Peking Union Medical College Hospital
RECRUITING
Beijing
The First People's Hospital of Foshan
RECRUITING
Foshan
TEDA International Cardiovascular Hospital
RECRUITING
Tianjin
Contact Information
Primary
LING YUAN
ling.yuan@sinotau.com
010-80716990
Time Frame
Start Date: 2025-11-14
Estimated Completion Date: 2027-10
Participants
Target number of participants: 395
Treatments
Experimental: enrolled participants with suspected or known CAD
Related Therapeutic Areas
Sponsors
Leads: Sinotau Pharmaceutical Group

This content was sourced from clinicaltrials.gov